Remdesivir, a much-touted experimental drug currently under investigation for the novel coronavirus, failed its first randomized clinical trial, according to draft documents published inadvertently by the World Health Organization (WHO). Apparently, the antiviral drug failed to improve patients’ condition or reduce the SARS-CoV-2 presence in the bloodstream. But a string of events raise the question: Is someone picking on Gilead? Reports early on of a group in China that sought to patent its remdesivir; a “failed” study in China due to lack of patients; and now this slip up via WHO. Just coincidental or something more?
Reported by the Financial Times yesterday, trading of the company’s shares was halted after falling by 6%. Apparently, the Chinese clinical trial investigating the drug failed to improve patients’ condition or reduce the pathogen’s presence in the blood stream. Somehow WHO prematurely posted a draft document prior to peer review. The publication Stat News was able to review the document before it was quickly taken down.
According to the report, the trial included 237 patients; 158 of the patients received remdesivir while the remainders did not. Apparently 18 patients had to be removed from the study due to significant side effects, reports the Financial Times.
Call to Action: Remdesivir represents one of the best candidates for a treatment for the novel coronavirus. TrialSite News continues to monitor various studies involving the drug and will update the network as data flows in.